Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method

Food and Healthcare Press Releases Friday August 11, 2017 15:23
ANN ARBOR, Michigan--11 Aug--PRNewswire/InfoQuest
Study published in Science magazine demonstrates how epigenetic markers can identify cell subtypes and regulatory elements that drive cellular diversity

Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing (NGS), today announced the launch of a new single-cell methylation sequencing method based on its Accel-NGS(R) Adaptase(TM) technology , an efficient and robust NGS-prep solution for whole-genome bisulfite sequencing at single-cell resolution. This new method enables the efficient analysis of different methylated regions across thousands of cells from heterogeneous tissues, while also addressing applications, such as cell classification, regulation of cellular mechanisms in normal tissue, epigenetic alterations in disease states and evolutionary conservation of epigenomic regulation.

Methylation is a stable biomarker that can be used to identify cell types and the regulatory elements underlying cell function. When coupled with single-cell RNA expression studies, single-cell methylation can elucidate the regulatory elements, in turn controlling the unique expression profiles of individual cells and differences between cells. Additionally, recent clinical studies have uncovered methylation patterns in diseases—such as cancer—which identify tumor type, assess tumor burden in liquid biopsies, and correlate with disease progression, prognosis and drug response.

This method was recently described in the Science paper entitled " Single Cell Methylomes Identify Neuronal Subtypes and Regulatory Elements in Mammalian Cortex " by collaborators at the Salk Institute, University of California San Diego and Swift Biosciences. The workflow combines fluorescence-activated cell sorting-based isolation, bisulfite conversion and Swift's Accel-NGS Adaptase module with other commercially available components. The published results demonstrated a greater than two-fold increase in read-mapping rates as compared to other methods; thereby, significantly improving the data output per sequencing run while reducing the overall cost.

"This is one of many scientific collaboration in which Swift technologies is pushing the boundaries of science," said Timothy Harkins, president and CEO of Swift Biosciences and co-author on the paper. "We are excited about new insights into basic cellular processes, and the profound, future impact it will have on precision medicine."

"Our proprietary Adaptase technology constructs high-complexity NGS libraries from low-input, single-stranded DNA," said Laurie Kurihara, PhD, senior director of research and development and co-author on the paper. "Our single-cell workflow has fewer steps than other methods and offers multiplexed, single-cell processing to provide greater productivity for high-throughput applications."

The Accel-NGS Adaptase Module is now commercially available.

Latest Press Release

Swift Announces the Highest Throughput Single-Cell Methyl-Seq Library Preparation Method

Study published in Science magazine demonstrates how epigenetic markers can identify cell subtypes and regulatory elements that drive cellular diversity Swift Biosciences, a leading provider of innovative library prep solutions for next-generation...

Making it Easier to Understand Nutrition Labels

The Nutrition Facts label can provide you with lots of useful information—as long as you know how to read it correctly. Reading nutrition labels can be a challenge, because it always seems confusing and complicated. Oftentimes, you are discouraged...

Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

- Collaboration furthers both parties' commitment to advance research and development for neglected diseases - Agreement focuses on optimizing vaccine process development and formulation and exchanging know-how Merck , a leading science and technology...

NICE Recommends Erbitux(R) in Combination with Platinum-Based Chemotherapy for the Treatment of Recurrent and/or Metastatic Head and Neck Cancer in the Oral Cavity

- Decision secures access to Erbitux(R) for new patients in England with oral cavity tumors - All patients currently receiving Erbitux(R) will have continued access Merck, a leading science and technology company, announced today that the National...

European Patent Office to Grant Merck#s Patent Application for CRISPR Technology

- Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Related patent application recently awarded in Australia; similar patents pending in other countries, favourable outcomes...

Related Topics